The Akt-GSK-3 signaling cascade in the actions of dopamine

Trends in Pharmacological Sciences

Volumn 28, Issue 4, 2007, Pages 166-172

  Beaulieu, Jean Martin ^a   Gainetdinov, Raul R ^a   Caron, Marc G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ISOPROPYL 6 METHYLERGOLINE 8 CARBOXYLIC ACID 2 HYDROXY 1 METHYLPROPYL ESTER; 2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; ALSTERPAULLONE; ARA 014418; BETA ARRESTIN 2; CLOZAPINE; CYCLIC AMP; DOPAMINE; DOPAMINE RECEPTOR; FENFLURAMINE; FLUOXETINE; FOSTRIECIN; G PROTEIN COUPLED RECEPTOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; HALOPERIDOL; IMIPRAMINE; INDIRUBIN; LITHIUM; OKADAIC ACID; OLANZAPINE; PROTEIN KINASE B; QUETIAPINE; RACLOPRIDE; RISPERIDONE; UNCLASSIFIED DRUG; ZIPRASIDONE;

DEPRESSION; KNOCKOUT MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

ANIMALS; ANTIPSYCHOTIC AGENTS; ARRESTINS; CYCLIC AMP; DOPAMINE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, DOPAMINE; SIGNAL TRANSDUCTION;

EID: 33947583891     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2007.02.006     Document Type: Review

References (62)

1. Missale C., et al. Dopamine receptors: from structure to function. Physiol. Rev. 78 (1998) 189-225
2. Greengard P. The neurobiology of slow synaptic transmission. Science 294 (2001) 1024-1030
3. Carlsson A. A paradigm shift in brain research. Science 294 (2001) 1021-1024
4. Gainetdinov R.R., et al. Monoamine transporter pharmacology and mutant mice. Trends Pharmacol. Sci. 23 (2002) 367-373
5. Heimer L., et al. Basal ganglia. In: Paxinos G. (Ed). The Rat Nervous System. 2nd edn (1995), Academic Press 579-629
6. Valjent E., et al. Role of the ERK pathway in psychostimulant-induced locomotor sensitization. BMC Neurosci. 7 (2006) 20
7. Valjent E., et al. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 491-496
8. Beaulieu J.M., et al. Paradoxical striatal cellular signaling responses to psychostimulants in hyperactive mice. J. Biol. Chem. 281 (2006) 32072-32080
9. Beaulieu J.M., et al. An Akt/β-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122 (2005) 261-273
10. Beaulieu J.M., et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 5099-5104
11. Arriza J.L., et al. The G-protein-coupled receptor kinases βARK1 and βARK2 are widely distributed at synapses in rat brain. J. Neurosci. 12 (1992) 4045-4055
12. Benovic J.L., et al. Cloning, expression, and chromosomal localization of β-adrenergic receptor kinase 2. A new member of the receptor kinase family. J. Biol. Chem. 266 (1991) 14939-14946
13. Gainetdinov R.R., et al. Desensitization of G protein-coupled receptors and neuronal functions. Annu. Rev. Neurosci. 27 (2004) 107-144
14. Shenoy S.K., and Lefkowitz R.J. Multifaceted roles of β-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. Biochem. J. 375 (2003) 503-515
15. Lohse M.J., et al. β-Arrestin: a protein that regulates β-adrenergic receptor function. Science 248 (1990) 1547-1550
16. Ferguson S.S., et al. Role of β-arrestin in mediating agonist-promoted G protein-coupled receptor internalization. Science 271 (1996) 363-366
17. Laporte S.A., et al. β-Arrestin/AP-2 interaction in G protein-coupled receptor internalization: identification of a β-arrestin binging site in β2-adaptin. J. Biol. Chem. 277 (2002) 9247-9254
18. Luttrell L.M., et al. Activation and targeting of extracellular signal-regulated kinases by β-arrestin scaffolds. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 2449-2454
19. Beaulieu J.M., and Caron M.G. β-Arrestin goes nuclear. Cell 123 (2005) 755-757
20. Shenoy S.K., et al. β-Arrestin-dependent, G protein-independent ERK1/2 activation by the β2 adrenergic receptor. J. Biol. Chem. 281 (2006) 1261-1273
21. Peppel K., et al. G protein-coupled receptor kinase 3 (GRK3) gene disruption leads to loss of odorant receptor desensitization. J. Biol. Chem. 272 (1997) 25425-25428
22. Gainetdinov R.R., et al. Muscarinic supersensitivity and impaired receptor desensitization in G protein-coupled receptor kinase 5-deficient mice. Neuron 24 (1999) 1029-1036
23. Gainetdinov R.R., et al. Dopaminergic supersensitivity in G protein-coupled receptor kinase 6-deficient mice. Neuron 38 (2003) 291-303
24. Jaber M., et al. Essential role of β-adrenergic receptor kinase 1 in cardiac development and function. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 12974-12979
25. Lefkowitz R.J., and Shenoy S.K. Transduction of receptor signals by β-arrestins. Science 308 (2005) 512-517
26. Bohn L.M., et al. Enhanced rewarding properties of morphine, but not cocaine, in β-arrestin-2 knock-out mice. J. Neurosci. 23 (2003) 10265-10273
27. Sotnikova T.D., et al. Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease. PLoS Biol. 3 (2005) e271
28. Emamian E.S., et al. Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia. Nat. Genet. 36 (2004) 131-137
29. Gould T.D., et al. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int. J. Neuropsychopharmacol. 7 (2004) 387-390
30. Hoeflich K.P., et al. Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature 406 (2000) 86-90
31. Prickaerts J., et al. Transgenic mice overexpressing glycogen synthase kinase 3β: a putative model of hyperactivity and mania. J. Neurosci. 26 (2006) 9022-9029
32. Lai W.S., et al. Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 16906-16911
33. Bajestan S.N., et al. Association of AKT1 haplotype with the risk of schizophrenia in Iranian population. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 141 (2006) 383-386
34. Schwab S.G., et al. Further evidence for association of variants in the AKT1 gene with schizophrenia in a sample of European sib-pair families. Biol. Psychiatry 58 (2005) 446-450
35. Ikeda M., et al. Association of AKT1 with schizophrenia confirmed in a Japanese population. Biol. Psychiatry 56 (2004) 698-700
36. Zhao Z., et al. Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction. Schizophr. Res. 84 (2006) 1-14
37. Kang U.G., et al. The effects of clozapine on the GSK-3-mediated signaling pathway. FEBS Lett. 560 (2004) 115-119
38. Li X., et al. Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. Int. J. Neuropsychopharmacol. 10 (2007) 7-19
39. Kapur S., and Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu. Rev. Med. 52 (2001) 503-517
40. Alimohamad H., et al. Antipsychotics alter the protein expression levels of β-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol. Psychiatry 57 (2005) 533-542
41. Karege F., et al. Alteration in kinase activity but not in protein levels of protein kinase B and glycogen synthase kinase-3β in ventral prefrontal cortex of depressed suicide victims. Biol. Psychiatry 61 (2007) 240-245
42. Li X., et al. In vivo regulation of glycogen synthase kinase-3β (GSK3β) by serotonergic activity in mouse brain. Neuropsychopharmacology 29 (2004) 1426-1431
43. Beaulieu J.M. Not only lithium: regulation of glycogen synthase kinase-3 by antipsychotics and serotonergic drugs. Int. J. Neuropsychopharmacol. 10 (2007) 3-6
44. Chalecka-Franaszek E., and Chuang D.M. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 8745-8750
45. Zhang F., et al. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J. Biol. Chem. 278 (2003) 33067-33077
46. Klein P.S., and Melton D.A. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 8455-8459
47. Phiel C.J., and Klein P.S. Molecular targets of lithium action. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 789-813
48. De Sarno P., et al. Regulation of Akt and glycogen synthase kinase-3β phosphorylation by sodium valproate and lithium. Neuropharmacology 43 (2002) 1158-1164
49. O'Brien W.T., et al. Glycogen synthase kinase-3β haploinsufficiency mimics the behavioral and molecular effects of lithium. J. Neurosci. 24 (2004) 6791-6798
50. 2 dopamine receptor third cytoplasmic loop with spinophilin, a protein phosphatase-1-interacting protein. J. Biol. Chem. 274 (1999) 19894-19900
51. Wang Q., et al. Spinophilin blocks arrestin actions in vitro and in vivo at G protein-coupled receptors. Science 304 (2004) 1940-1944
52. Liu S., et al. A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat. Med. 11 (2005) 952-958
53. Kang J., et al. A nuclear function of β-arrestin 1 in GPCR signaling: regulation of histone acetylation and gene transcription. Cell 123 (2005) 833-847
54. Chao J., and Nestler E.J. Molecular neurobiology of drug addiction. Annu. Rev. Med. 55 (2004) 113-132
55. Stelling J., et al. Robustness of cellular functions. Cell 118 (2004) 675-685
56. Scheid M.P., and Woodgett J.R. PKB/AKT: functional insights from genetic models. Nat. Rev. Mol. Cell Biol. 2 (2001) 760-768
57. Chen M.J., and Russo-Neustadt A.A. Exercise activates the phosphatidylinositol 3-kinase pathway. Brain Res. Mol. Brain Res. 135 (2005) 181-193
58. Frame S., and Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359 (2001) 1-16
59. Ahn S., et al. Differential kinetic and spatial patterns of β-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J. Biol. Chem. 279 (2004) 35518-35525
60. Valjent E., et al. Involvement of the extracellular signal-regulated kinase cascade for cocaine-rewarding properties. J. Neurosci. 20 (2000) 8701-8709
61. Svenningsson P., et al. Diverse psychotomimetics act through a common signaling pathway. Science 302 (2003) 1412-1415
62. 3 dopamine receptors in vivo. J. Neurosci. 27 (2007) 881-885